• Nicolás Triantafilo, Mauricio Sarmiento, James Campbell, Patricio Rojas, María José García, Vicente Sandoval, Pablo Bertín, Mauricio Ocqueteau, María Concepciãn Risueño, Isabel Rodríguez, and Mauricio Galleguillos.
• Hematología, Red de Salud UCChristus, Santiago, Chile.
• Rev Med Chil. 2022 May 1; 150 (5): 643649643-649.

BackgroundAcute myeloid leukemia (AML) is the most common leukemia in adults.AimTo Describe our population of patients with AML and report the outcomes of our treatments.Material And MethodsReview of electronic clinical records of 114 patients with AML with a median age of 57 years (59% men).ResultsSeventeen percent of patients were classified as low risk, 38% as intermediate risk and 33% as high risk. Seventy-six percent of patients were treated with intensive chemotherapy. Five years overall survival according to cytogenetic risk was 59, 41, and 12% in low, intermediate, and high-risk patients, respectively. The outcomes were better in patients under 60 years. The median survival of patients treated with intensive chemotherapy aged less than 60 years and 60 years and above was 3.4 and 1 year, respectively.ConclusionsOur results are comparable to those reported in developed countries. Improving the survival of patients 60 years and older is our main challenge.

11 keywords...

hide…